FDA Guides Drugmakers on Bullseye Rash Lyme Fixes
Published Date: 6/26/2025
Notice
Summary
The FDA just released final advice to help drug makers create treatments for early Lyme disease, especially when it shows up as a bullseye rash called erythema migrans. This update affects companies working on Lyme disease drugs and aims to speed up safe, effective treatments hitting the market. No big cost changes yet, but faster drug development means better care for patients sooner!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA final guidance for Lyme drugs
The FDA released a final guidance titled "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment" to help drug sponsors with the clinical development of treatments for early Lyme disease shown by an erythema migrans (EM) rash. This final guidance formalizes the draft guidance that was issued on February 1, 2023.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in